$21.34
-0.06[-0.28%]
Last update: 8:23AM Get Real Time Here
Fusion Pharmaceuticals
(NASDAQ:FUSN)Latest News for Fusion Pharmaceuticals Stock (NASDAQ:FUSN)
Fusion Pharmaceuticals Stock (NASDAQ: FUSN)
Categories: All
Friday, April 26, 2024
Tuesday, April 16, 2024
Thursday, April 11, 2024
Tuesday, April 09, 2024
Tuesday, April 02, 2024
Thursday, March 21, 2024
Wednesday, March 20, 2024
- Recap: Fusion Pharmaceuticals Q4 EarningsBenzinga Insights - Mar 20, 2024, 5:30PM
- Fusion Pharmaceuticals Q4 2023 GAAP EPS $(0.39) Misses $(0.34) EstimateBenzinga Newsdesk - Mar 20, 2024, 4:22PM
- Raymond James Downgrades Fusion Pharmaceuticals to Market PerformBenzinga Newsdesk - Mar 20, 2024, 10:04AM
- B. Riley Securities Downgrades Fusion Pharmaceuticals to Neutral, Raises Price Target to $23Benzinga Newsdesk - Mar 20, 2024, 10:02AM
- Truist Securities Downgrades Fusion Pharmaceuticals to Hold, Raises Price Target to $21-REPORT RELEASED ON 19TH MARCH 2024Benzinga Newsdesk - Mar 20, 2024, 8:46AM
- Unveiling 11 Analyst Insights On Fusion PharmaceuticalsBenzinga Insights - Mar 20, 2024, 8:01AM
- RBC Capital Downgrades Fusion Pharmaceuticals to Sector Perform, Raises Price Target to $21Benzinga Newsdesk - Mar 20, 2024, 7:26AM
- JonesTrading Downgrades Fusion Pharmaceuticals to HoldBenzinga Newsdesk - Mar 20, 2024, 4:45AM
Tuesday, March 19, 2024
- Nasdaq Turns Higher; Caleres Posts Upbeat Q4 ResultsAvi Kapoor - Mar 19, 2024, 3:02PM
- Why Peraso Shares Are Trading Lower By Over 23%? Here Are Other Stocks Moving In Tuesday's Mid-Day SessionAvi Kapoor - Mar 19, 2024, 1:48PM
- 12 Health Care Stocks Moving In Tuesday's Intraday SessionBenzinga Insights - Mar 19, 2024, 1:31PM
- Dow Jumps 200 Points; Core & Main Shares Gain After Q4 ResultsAvi Kapoor - Mar 19, 2024, 12:54PM
- Truist Securities Downgrades Fusion Pharmaceuticals to Hold, Raises Price Target to $21Benzinga Newsdesk - Mar 19, 2024, 11:56AM
- William Blair Downgrades Fusion Pharmaceuticals to Market PerformBenzinga Newsdesk - Mar 19, 2024, 11:03AM
- Brookline Capital Downgrades Fusion Pharmaceuticals to HoldBenzinga Newsdesk - Mar 19, 2024, 10:58AM
- Raymond James Downgrades Fusion Pharmaceuticals to Market PerformBenzinga Newsdesk - Mar 19, 2024, 10:56AM
- Jefferies Downgrades Fusion Pharmaceuticals to Hold, Raises Price Target to $21Benzinga Newsdesk - Mar 19, 2024, 10:55AM
- Wedbush Downgrades Fusion Pharmaceuticals to Neutral, Announces $24 Price TargetBenzinga Newsdesk - Mar 19, 2024, 10:20AM
- National CineMedia Reports Upbeat Results, Joins Nordstrom, Core & Main And Other Big Stocks Moving Higher On TuesdayAvi Kapoor - Mar 19, 2024, 10:03AM
- Nasdaq Down 100 Points; US Housing Starts Surge In FebruaryAvi Kapoor - Mar 19, 2024, 9:40AM
- 12 Health Care Stocks Moving In Tuesday's Pre-Market SessionBenzinga Insights - Mar 19, 2024, 9:05AM
- Nvidia To Rally Around 10%? Here Are 10 Top Analyst Forecasts For TuesdayAvi Kapoor - Mar 19, 2024, 8:34AM
- Why Fusion Pharmaceuticals Shares Are Trading Higher By Around 95%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Mar 19, 2024, 8:10AM
- US Stocks Poised For Lower Open As Fed Jitters Dampen Tech Hopes; Oil Rally Pauses, Bitcoin Slides 8%Shanthi Rexaline - Mar 19, 2024, 7:41AM
- Fusion Pharmaceuticals shares are trading higher after the company announced that it entered into a definitive agreement to be acquired by AstraZeneca. Also, Leerink Partners downgraded the stock from Outperform to Market Perform but raised its price target from $17 to $21.Benzinga Newsdesk - Mar 19, 2024, 7:34AM
- AstraZeneca's $2.4B Fusion Pharmaceuticals' Acquisition Signals Shift In Efforts From Traditional Regimens For More Targeted Cancer TreatmentsVandana Singh - Mar 19, 2024, 7:26AM
- Leerink Partners Downgrades Fusion Pharmaceuticals to Market Perform, Raises Price Target to $21Benzinga Newsdesk - Mar 19, 2024, 7:16AM
- Fusion Pharmaceuticals to be Acquired by AstraZeneca for $2B Plus Milestones in Oncology BreakthroughBenzinga Newsdesk - Mar 19, 2024, 3:06AM
Tuesday, March 05, 2024
Monday, March 04, 2024
Friday, February 16, 2024
Friday, January 26, 2024
Friday, January 19, 2024
Friday, January 05, 2024
- Raymond James Maintains Strong Buy on Fusion Pharmaceuticals, Raises Price Target to $16Benzinga Newsdesk - Jan 5, 2024, 2:30PM
- Oppenheimer Maintains Outperform on Fusion Pharmaceuticals, Raises Price Target to $15Benzinga Newsdesk - Jan 5, 2024, 1:26PM
- Why Dermata Therapeutics Shares Are Trading Higher By Over 57%; Here Are 20 Stocks Moving PremarketAvi Kapoor - Jan 5, 2024, 8:03AM